Bone resorption and bone metastasis risk

Katlynn M. Mathis, Kathleen Sturgeon, Renate Winkels, Joachim Wiskemann, Mary Jane De Souza, Kathryn Schmitz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Breast cancer tumors have a tendency to metastasize to the bone. After development of a bone metastasis, the median survival time is 40 months. Currently, little is known about the modifiable risk factors for developing bone metastases in women diagnosed with breast cancer. One possible modifiable risk factor is increased bone resorption. Increased bone resorption is caused by an imbalance between osteoblasts and osteoclasts favoring osteoclast-driven bone resorption. Osteoclast activity results in the release of growth factors from the bony matrix that are requirement for successful breast cancer tumor cell proliferation within the bone. Mice studies have shown that mice that have been genetically engineered to have higher bone mineral density, and thus lower bone resorption, have a decreased incidence of bone metastases. Alternatively, mice genetically engineered to have lower bone mineral density or increased bone resorption have a higher incidence of bone metastases. In human studies, antiosteoporotic drugs have been shown to decrease osteoclast activity and prevent bone metastases. These studies suggest that increased osteoclast activity, which results in low bone mineral density, may be a modifiable risk factor for developing bone metastases in women with breast cancer. Women undergoing chemotherapy for breast cancer develop low bone mineral density in response to the direct effects of chemotherapeutic drugs on bone cells—including osteoclasts, osteoblasts, and osteocytes—and through the decrease in circulating estrogen as a result of chemotherapy-induced ovarian dysfunction. Therefore, it is important for future studies to determine the risk of developing bone metastases associated with increasing bone resorption as measured by low or decreasing bone mineral density in women diagnosed with breast cancer, as well as to determine the best intervention(s) to promote a balance between osteoclasts and osteoblasts to favor osteoblast activity during chemotherapy treatment.

Original languageEnglish (US)
Pages (from-to)36-41
Number of pages6
JournalMedical Hypotheses
Volume118
DOIs
StatePublished - Sep 1 2018

Fingerprint

Bone Resorption
Osteoclasts
Neoplasm Metastasis
Bone and Bones
Breast Neoplasms
Bone Density
Osteoblasts
Drug Therapy
Bone Development
Incidence
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins
Estrogens
Cell Proliferation
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Mathis, Katlynn M. ; Sturgeon, Kathleen ; Winkels, Renate ; Wiskemann, Joachim ; De Souza, Mary Jane ; Schmitz, Kathryn. / Bone resorption and bone metastasis risk. In: Medical Hypotheses. 2018 ; Vol. 118. pp. 36-41.
@article{e95b7ad814dd4bc8b3632f490307db1e,
title = "Bone resorption and bone metastasis risk",
abstract = "Breast cancer tumors have a tendency to metastasize to the bone. After development of a bone metastasis, the median survival time is 40 months. Currently, little is known about the modifiable risk factors for developing bone metastases in women diagnosed with breast cancer. One possible modifiable risk factor is increased bone resorption. Increased bone resorption is caused by an imbalance between osteoblasts and osteoclasts favoring osteoclast-driven bone resorption. Osteoclast activity results in the release of growth factors from the bony matrix that are requirement for successful breast cancer tumor cell proliferation within the bone. Mice studies have shown that mice that have been genetically engineered to have higher bone mineral density, and thus lower bone resorption, have a decreased incidence of bone metastases. Alternatively, mice genetically engineered to have lower bone mineral density or increased bone resorption have a higher incidence of bone metastases. In human studies, antiosteoporotic drugs have been shown to decrease osteoclast activity and prevent bone metastases. These studies suggest that increased osteoclast activity, which results in low bone mineral density, may be a modifiable risk factor for developing bone metastases in women with breast cancer. Women undergoing chemotherapy for breast cancer develop low bone mineral density in response to the direct effects of chemotherapeutic drugs on bone cells—including osteoclasts, osteoblasts, and osteocytes—and through the decrease in circulating estrogen as a result of chemotherapy-induced ovarian dysfunction. Therefore, it is important for future studies to determine the risk of developing bone metastases associated with increasing bone resorption as measured by low or decreasing bone mineral density in women diagnosed with breast cancer, as well as to determine the best intervention(s) to promote a balance between osteoclasts and osteoblasts to favor osteoblast activity during chemotherapy treatment.",
author = "Mathis, {Katlynn M.} and Kathleen Sturgeon and Renate Winkels and Joachim Wiskemann and {De Souza}, {Mary Jane} and Kathryn Schmitz",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.mehy.2018.06.013",
language = "English (US)",
volume = "118",
pages = "36--41",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

Bone resorption and bone metastasis risk. / Mathis, Katlynn M.; Sturgeon, Kathleen; Winkels, Renate; Wiskemann, Joachim; De Souza, Mary Jane; Schmitz, Kathryn.

In: Medical Hypotheses, Vol. 118, 01.09.2018, p. 36-41.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone resorption and bone metastasis risk

AU - Mathis, Katlynn M.

AU - Sturgeon, Kathleen

AU - Winkels, Renate

AU - Wiskemann, Joachim

AU - De Souza, Mary Jane

AU - Schmitz, Kathryn

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Breast cancer tumors have a tendency to metastasize to the bone. After development of a bone metastasis, the median survival time is 40 months. Currently, little is known about the modifiable risk factors for developing bone metastases in women diagnosed with breast cancer. One possible modifiable risk factor is increased bone resorption. Increased bone resorption is caused by an imbalance between osteoblasts and osteoclasts favoring osteoclast-driven bone resorption. Osteoclast activity results in the release of growth factors from the bony matrix that are requirement for successful breast cancer tumor cell proliferation within the bone. Mice studies have shown that mice that have been genetically engineered to have higher bone mineral density, and thus lower bone resorption, have a decreased incidence of bone metastases. Alternatively, mice genetically engineered to have lower bone mineral density or increased bone resorption have a higher incidence of bone metastases. In human studies, antiosteoporotic drugs have been shown to decrease osteoclast activity and prevent bone metastases. These studies suggest that increased osteoclast activity, which results in low bone mineral density, may be a modifiable risk factor for developing bone metastases in women with breast cancer. Women undergoing chemotherapy for breast cancer develop low bone mineral density in response to the direct effects of chemotherapeutic drugs on bone cells—including osteoclasts, osteoblasts, and osteocytes—and through the decrease in circulating estrogen as a result of chemotherapy-induced ovarian dysfunction. Therefore, it is important for future studies to determine the risk of developing bone metastases associated with increasing bone resorption as measured by low or decreasing bone mineral density in women diagnosed with breast cancer, as well as to determine the best intervention(s) to promote a balance between osteoclasts and osteoblasts to favor osteoblast activity during chemotherapy treatment.

AB - Breast cancer tumors have a tendency to metastasize to the bone. After development of a bone metastasis, the median survival time is 40 months. Currently, little is known about the modifiable risk factors for developing bone metastases in women diagnosed with breast cancer. One possible modifiable risk factor is increased bone resorption. Increased bone resorption is caused by an imbalance between osteoblasts and osteoclasts favoring osteoclast-driven bone resorption. Osteoclast activity results in the release of growth factors from the bony matrix that are requirement for successful breast cancer tumor cell proliferation within the bone. Mice studies have shown that mice that have been genetically engineered to have higher bone mineral density, and thus lower bone resorption, have a decreased incidence of bone metastases. Alternatively, mice genetically engineered to have lower bone mineral density or increased bone resorption have a higher incidence of bone metastases. In human studies, antiosteoporotic drugs have been shown to decrease osteoclast activity and prevent bone metastases. These studies suggest that increased osteoclast activity, which results in low bone mineral density, may be a modifiable risk factor for developing bone metastases in women with breast cancer. Women undergoing chemotherapy for breast cancer develop low bone mineral density in response to the direct effects of chemotherapeutic drugs on bone cells—including osteoclasts, osteoblasts, and osteocytes—and through the decrease in circulating estrogen as a result of chemotherapy-induced ovarian dysfunction. Therefore, it is important for future studies to determine the risk of developing bone metastases associated with increasing bone resorption as measured by low or decreasing bone mineral density in women diagnosed with breast cancer, as well as to determine the best intervention(s) to promote a balance between osteoclasts and osteoblasts to favor osteoblast activity during chemotherapy treatment.

UR - http://www.scopus.com/inward/record.url?scp=85048817571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048817571&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2018.06.013

DO - 10.1016/j.mehy.2018.06.013

M3 - Article

C2 - 30037612

AN - SCOPUS:85048817571

VL - 118

SP - 36

EP - 41

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -